Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Biologics
  4.  » 
  5. Drug Substance
  6.  » 
  7. Bioconjugate Development
  8.  » Partnering / Pipeline

Antibody-drug Conjugates & Bioconjugates


Catalent Biologics offers flexible options for our partners to employ SMARTag® technology in their bioconjugate and ADC programs, including broad research licenses, target-specific commercial licenses, co-development / product participation deals, and bundled deals including GPEx® cell line development, antibody manufacturing, and analytical services.

Please click here to inquire about potential SMARTag® collaboration opportunities:

  • Licensing an asset from our pipeline (including molecules against both solid and hematopoietic tumors)
  • Collaborating with us to develop de novo assets using our SMARTag® platform technology and ADC development expertise
Chart indicating the SMARTag ADC Bioconjugate pipline from discovery / optimization, to pre-clinical development, to Phase 1.